To include your compound in the COVID-19 Resource Center, submit it here.

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

VCs led by MPM, Deerfield and Droia believe Frontier can reach previously undruggable targets through chemoproteomics

With $67 million in series A funding, newly launched Frontier Medicines Corp. believes that by using its massive database of protein binding hot spots and applying machine learning to its library of covalent compounds, the chemoproteomics company can reach previously undruggable targets.

Founded in 2018 with an initial investment from MPM Capital, South San Francisco, Calif.-based Frontier has licensed technology from the University of California Berkeley, where two of its co-founders are

Read the full 717 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE